Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy

Journal of Virology

Volumn 75, Issue 14, 2001, Pages 6410-6417

  Hance, A J ^a   Lemiale, V ^a   Izopet, J ^a   Lecossier, D ^a   Joly, V ^a   Massip, P ^a   Mammano, F ^a   Descamps, D ^a   Brun Vezinet F ^a   Clavel, F ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ARTICLE; DRUG WITHDRAWAL; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; PROTEASE INHIBITORS; TIME FACTORS; TREATMENT REFUSAL;

EID: 0034987622     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.14.6410-6417.2001     Document Type: Article

References (33)

1. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
2. Individual contributions of mutant protease and reverse transcriptase to vital infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
3. Mismatch amplification mutation assay (MAMA): Application to the c-H-ras gene
4. The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies
5. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
6. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
7. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
8. Resistance profiles in patients with viral rebound on potent antiretroviral therapy
9. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
10. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
11. Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients
12. RNA virus mutations and fitness for survival
13. Minimizing DNA recombination during long RT-PCR
14. A novel method for real time quantitative RT-PCR
15. HIV-1 isolates are rapidly evolving quasispecies: Evidence for viral mixtures and preferred nucleotide substitutions
16. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples
17. Real time quantitative PCR
18. The year in review: Antiretroviral treatment
19. Extension of base mispairs by Taq DNA polymerase: Implications for single nucleotide discrimination in PCR
20. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen
21. Stimulation and suppression of PCR-mediated recombination
22. Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency virus type 1 model studies
23. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
24. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes
25. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: Virus fitness in the absence and in the presence of drug
26. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations
27. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
28. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
29. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
30. Oligomerization within virions and subcellular localization of human immunodeficiency virus type 1 integrase
31. Mutations in retroviral genes associated with drug resistance: 2000-2001 update
32. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype
33. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo